Join us for an exclusive webinar to uncover how our next-generation humanized mouse models, HUGO-GT™, are reshaping neuroscience research. Explore how these advanced humanization models are revolutionizing neurological disease research with our improved humanization strategy that can accelerate your research in neuroscience and gene therapy.
1. Introduction to HUGO-GT™ Humanized Mouse Models
Discover the transformative science behind Cyagen’s HUGO-GT™ platform, which enables precise genetic modifications for developing highly relevant disease models for neuroscience research. Our proprietary TurboKnockout ES cell gene-targeting technology is used to
replace mouse genes with the corresponding full-length human genes (both wt & mut forms), including
exons, introns, and UTRs.
2. Case Study: hMECP2 Model
Learn about our case study of the hMECP2 model, a breakthrough tool for understanding neurodevelopmental disorders related to MECP2. Discover how HUGO-GT™ models are paving the way for new insights into gene expression and neurological diseases.
3. Neuroscience Models Overview
Gain a comprehensive understanding of Cyagen’s neuroscience-related HUGO-GT™ models, supporting studies in Alzheimer’s disease, epilepsy, and other conditions.
4. Introduction to Our CRO Platform
Get a detailed look at Cyagen’s dedicated CRO platform for neuroscience research, designed to support innovative studies using advanced neurological disease models. See how our state-of-the-art facilities and neurobehavioral analysis platforms can support cutting-edge studies in neurological disease models.
This webinar is ideal for researchers, scientists, and professionals working in genetics, neuroscience, and biomedical research. Discover how HUGO-GT™ mouse models serve as cutting-edge tools for preclinical research on gene therapy drugs like ASO, CRISPR, siRNA, AAV, and LNP across oncology, immunology, neuroscience, and more. Don’t miss out on the opportunity to discover how Cyagen’s cutting-edge solutions can accelerate your research.
Dr. Morris Cui is the Study Director of the Cell and Gene Therapy Department at Cyagen, where he leads cutting-edge research in neuroscience and gene therapy. Morris earned his Ph.D. from the University of Munich in 2023, having conducted extensive research at the Center for Neurodegenerative Diseases, where he focused on the pathological mechanisms and experimental therapies for neurodegenerative diseases, particularly Alzheimer's and Parkinson's diseases.
With over five years of research experience in neuroscience and two years of clinical practice as a neurologist, Morris has developed deep expertise in both the scientific and clinical aspects of neurodegenerative diseases. He is also highly proficient in conducting related cell and animal experiments to study disease mechanisms and test therapeutic strategies.
Cyagen has established over 80 fully Humanized Genomic Ortholog for Gene Therapy (HUGO-GT™) mouse models that offer a higher degree of humanization compared to traditional models to support research on human rare diseases and improve therapeutic translation to clinical trials. HUGO-GT™ mouse models serve as cutting-edge humanized modeling tools for preclinical research on gene therapy drugs like ASO, CRISPR, siRNA, AAV, and LNP across oncology, immunology, neuroscience, and more.
Our HUGO-GT™ fully humanized genome mice are developed based on our proprietary TurboKnockout-Pro ES cell gene-targeting technology to achieve in situ replacement of mouse genes, encompassing a broader range of intervention targets and providing full coverage of pathogenic gene mutation sites-all without patent or ownership disputes. The fully humanized target genes within these models are consistent with the pathogenic genes carried by humans and cover the majority of drug targets, significantly enhancing screening efficiency for various types of preclinical drug experiments.
Cyagen is a global leader in custom genetically modified rodent models and cell and gene therapy (CGT) R&D. With 17+ years of experience, we provide customized disease model development via CRISPR-Pro, TurboKnockout, and transgenic technologies, while our Knockout Catalog Models feature over 16,000 ready-to-use KO/cKO mouse strains. Our Humanized Genomic Ortholog for Gene Therapy (HUGO-GT™) program offers a higher degree of humanization compared to traditional models, achieving fully-genomically humanized mouse models that facilitate a more robust understanding of the effects of gene mutations and enhance the translatability of therapeutics from preclinical studies to clinical applications.
Beyond research model generation, our one-stop CRO solutions include AAV discovery, an "AI+CGT" platform to accelerate CGT research, drug efficacy studies, and more. Our Rare Disease Data Center (RDDC) supports rare disease research with AI-driven bioinformatics tools. Our cutting-edge gene therapy and drug development research platforms are trusted by partners worldwide. Contact us for a free consultation.
